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OBJECTIVE—To examine the long-term safety and efficacy of three antipsychotics in early-onset
schizophrenia spectrum disorders (EOSS).
METHOD—Patients (age 8–19 years) who had improved during an 8-week, randomized double-
blind acute trial of olanzapine, risperidone, or molindone (plus benztropine) were eligible to continue
on the same medication for up to 44 additional weeks under double-blind conditions. Adjunctive
medications were allowed following defined algorithms. Standardized symptom, safety, and
functional assessments were conducted every 4 weeks.
RESULTS—Of the 116 youth randomized in the acute trial, 54 entered maintenance treatment
(molindone, N=20; olanzapine, N=13; risperidone, N=21). Fourteen (26%) completed 44 weeks of
treatment. Adverse effects (N=15), inadequate efficacy (N=14), or study non-adherence (N=8) were
the most common reasons for discontinuation. The three treatment arms did not significantly differ
in symptom reduction or time to discontinuation. Akathisia was more common with molindone and
elevated prolactin concentrations more common with risperidone. Although weight gain and
metabolic adverse events had occurred more often with olanzapine and risperidone during the acute
trial, no significant between-drug differences emerged in most of these parameters during
maintenance treatment.
CONCLUSIONS—Only 12 % of youth with EOSS continued on their originally randomized
treatment at 52 weeks. No agent demonstrated superior efficacy, and all were associated with side
effects, including weight gain. Improved treatments are needed for EOSS.
Keywords
adolescent; schizophrenia; schizoaffective disorder; antipsychotic; treatment
INTRODUCTION
Early-onset schizophrenia spectrum disorders (EOSS; onset < 18 years) are associated with
disabling symptomatology, marked functional impairments, and a poor prognosis.1,2 Safe and
effective treatments are needed to improve the outcomes of these vulnerable youths.
In the largest publicly funded trial conducted to date, our Treatment of Early-Onset
Schizophrenia Spectrum Disorders (TEOSS) study compared the acute effectiveness and safety
of antipsychotics in youth with EOSS. Overall, approximately 50 % of subjects responded to
the initially randomized treatment.3 Two “second generation” antipsychotics, risperidone and
olanzapine, were not superior to a “first generation” antipsychotic, molindone, in symptom
diminution or proportion of treatment responders. Both risperidone and olanzapine were
associated with greater degrees of weight gain than molindone. Molindone was associated with
higher rates of akathisia. Olanzapine treatment also led to significant increases in fasting
cholesterol, low density lipoprotein, insulin, and liver transaminases. Given these risks, the
study’s Data and Safety Monitoring Board discontinued further randomizations into the
olanzapine arm midway through the study and required implementation of more rigorous
procedures to assess the benefit/risk ratio in all participants.
As schizophrenia is a chronic condition, long-term treatment is likely to be needed in EOSS.
1 There have been numerous randomized trials to determine the long-term effectiveness of
antipsychotic agents in adults with schizophrenia, most of which have described few, if any,
differences in outcomes between these medications (reviewed by Johnsen & Jørgensen).4 To
our knowledge, there are no long-term, double-blind, prospective studies that have examined
the effectiveness and safety of different antipsychotic agents for up to one year in juveniles.
We describe the results of maintenance treatment in youths who participated in the acute
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TEOSS trial and were maintained on their original randomized treatment as maintenance
therapy.
Our approach to these analyses was mainly descriptive. We anticipated that the benefits
observed during acute treatment would persist and that the three medications would
demonstrate different tolerability profiles, with olanzapine and risperidone being associated




The TEOSS study methods have been described in detail in prior publications.3,5 In this report
we focus on the 44-week, double-blind extension phase that followed the 8-week, double-blind
acute trial. The primary results of the acute study have been described previously.3
During maintenance, youths continued to receive the same antipsychotic drug that they were
administered during the acute phase. Treatment response and side effects were assessed every
4 weeks. Patients could be seen more frequently if clinically indicated.
All study procedures were reviewed and approved by the institutional review boards at each
of the 4 study sites. Participant safety was also monitored by the National Institute of Mental
Health (NIMH) Data and Safety Monitoring Board. All participants and their guardians
provided written informed assent and consent, respectively.
For the sake of clarity, interventions prior to receiving therapy in the acute study will be denoted
as occurring at the baseline time point. Weeks 8–52 specifically refer to time points in this
maintenance study. In other words, week eight is the start of the maintenance study.
Participants
Youths, ages 8 to 19 years, who met diagnostic criteria for schizophrenia, schizophreniform
disorder, or schizoaffective disorder were enrolled in the acute 8-week trial. Diagnostic
methods, inclusion/exclusion criteria, and baseline characteristics of the sample are described
elsewhere.2, 3, 5 After acute treatment, participants who: 1) were adequately tolerating their
initially assigned treatment; and 2) had an adequate response to treatment (defined by a 20%
reduction in baseline Positive and Negative Syndrome Scale (PANSS)6 score plus a Clinical
Global Impression-Improvement (CGI-I)7 score of 1 or 2, indicative of being “very much
improved” or “much improved”) were eligible to continue on maintenance therapy. In addition,
seven patients who did not meet the acute phase responder criteria but who had improved
sufficiently were allowed to continue into maintenance therapy because it was felt to be in the
best clinical interest of the patients.
Pharmacological Treatments
Subjects were treated with flexible doses of molindone (10–140 mg/day), olanzapine (2.5–20
mg/day), or risperidone (0.5–6 mg/day). Dose increases were based on clinical need. All youths
who were assigned to treatment with molindone also received 0.5 mg twice daily of benztropine
in order to reduce the risk of extrapyramidal symptoms (EPS). All other patients received
matching placebo. Flexible dosing within these dose ranges was continued during the
maintenance phase.
Adjunctive psychotropics permitted included: benztropine or trihexyphenidyl (for EPS);
propranolol (for akathisia); lorazepam or clonazepam (for agitation and insomnia); fluoxetine,
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sertraline, or citalopram (serotonin selective reuptake inhibitors, “SSRIs,” for depression), and
valproate or lithium (“mood stabilizers” for manic symptoms). Diphenydramine could be
prescribed for upper respiratory symptoms or insomnia. It is classified as a “psychotropic” for
this manuscript due to the fact that diphenhydramie can also reduce EPS (although it was not
used primarily for that purpose in this trial). Trazodone could be prescribed for insomnia. These
adjunctive agents could be discontinued if they were no longer clinically indicated.
Efficacy Measures and Outcomes
The PANSS (a 30-item, clinician-rated scale used for the comprehensive assessment of
psychotic symptoms), the Brief Psychiatric Rating Scale for Children (BPRS-C)8 (an
assessment for the severity of 18 common psychiatric and behavioral problems with subscales
for positive and negative symptoms, depression, and mania), and the Clinical Global
Impression-Severity (CGI-S)7 (measurement of illness severity) were administered at all study
visits. The Child and Adolescent Functional Assessment Scale (CAFAS)9 was administered
at baseline and weeks 8, 24 and 52/end of study (EOS).
Adverse Event and Safety Monitoring
In addition to open-ended inquiry about the presence of adverse events, the Monitoring of Side
Effects Scale (MOSES)10 was also used to ascertain adverse events. Events of moderate
severity or higher which were not judged to be related to the underlying psychopathology were
recorded as adverse events. EPS were monitored using the Neurological Rating Scale (NRS),
11 the Barnes Akathisia Scale (BAS),12 and the Abnormal Involuntary Movement Scale
(AIMS).7 Vital signs, height, weight, and body mass index (BMI),13 were also assessed. With
the exception of the AIMS (obtained at baseline and weeks 8, 24, 36, and 52/end of study),
other measures were obtained at each visit.
Between February 2002 and December 2005, subjects who gained more than 25% of their pre-
treatment body weight were reviewed by the investigators in order to determine whether study
withdrawal was appropriate. In December 2005, all subjects who had gained more than 7% of
their body weight were reviewed in order to determine whether the apparent benefits
experienced by the participants justified the associated risks. If a participant’s BMI was ≥ 30
kg/m2 and the participant had gained more than 30% of their body weight since their pre-
treatment assessment, treatment discontinuation was required regardless of symptom response.
Electrocardiograms (ECGs) were obtained at baseline and weeks 8, 24, 36, 52/ end of study.
ECGs were read by a pediatric specialist in order to monitor for possible QTc prolongation.
Routine fasting blood and urine chemistries were obtained at baseline and weeks 8, 24, 36, and
52/end of study. Prolactin and thyroid-stimulating hormone (TSH) were measured at baseline,
week 8, and week 52/end of study. Prolactin was also measured at weeks 24 and 36. Also, urine
toxicology screens and pregnancy tests were collected at weeks 8 and 52/end of study. If a
female subject was receiving adjunctive valproate or lithium, additional pregnancy tests were
done at weeks 24 and 36.
Statistical Analyses
Continuous variables were analyzed via F-tests in a one-way analysis of variance (ANOVA)
with last observation carried forward change from baseline as outcome. To investigate possible
violations of distributional assumptions due to small treatment group sizes, a nonparametric
Kruskal-Wallis (three groups) or Wilcoxon test (2 groups) was also performed as a sensitivity
analysis for each continuous outcome. Total scores for patients with missing items in their
PANSS or CAFAS evaluations were weighted to reflect the number of items completed. Data
for glucose, cholesterol, triglycerides, HDL, and LDL were included only if the patient was
fasting at the time of laboratory data collection.
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Categorical outcomes, including proportions of patients taking concomitant medications or
experiencing adverse events, were compared across treatment groups using exact chi-square
tests. Concomitant medications were categorized post-hoc by the lead investigator using the
text descriptions given in the database. Adverse events were categorized using their assigned
MOSES category, except those with MOSES category “Other”, for which a new adverse event
category was created post-hoc by the lead investigator. To assess the presence of tardive
dyskinesia, patient records were reviewed post-hoc by the investigators for any patient having
1) two or more items on the AIMS with scores 2 or higher, 2) one or more items on the AIMS
with score 3 or higher, or 3) a score on any of the neurological scales of the MOSES of 3 or
higher.
Time to discontinuation was estimated via Kaplan Meier survival curves and compared among
treatment groups using a log-rank test. Time to discontinuation for each patient was computed
by subtracting the dates of the baseline and termination study visits.
Due to the exploratory and descriptive purposes of this paper, no adjustments for multiple
comparisons were made. All analyses were conducted using SAS software (Cary, NC) version
9.
RESULTS
Subjects and Baseline Characteristics
Figure 1 shows subject disposition during TEOSS. Of the 116 patients initially receiving
therapy, 54 (47%) entered this continuation study. Demographic and clinical characteristics of
the entire TEOSS patient population at baseline are described elsewhere.2
Patients who only participated in the acute trial showed few statistically significant differences
in demographics or baseline clinical features when compared to patients who continued with
maintenance therapy. Youth taking olanzapine that entered this extension study had
significantly lower mean baseline PANSS positive symptom scores than those who only
participated in the acute trial (23.6±5.1, 28.1±5.8, respectively; p=0.028). Conversely, for
patients treated with risperidone, subjects receiving long-term treatment had higher mean
baseline PANSS positive scores than those who only participated in the acute trial (28.7±6.4,
24.7±5.9; p=0.041).
Additionally, patients receiving long-term olanzapine treatment had lower systolic blood
pressure (108.9±7.5, 118.5±13.3, p=0.023) than the olanzapine patients who only participated
in the acute trial. Patients treated with long-term molindone had lower baseline sitting pulse
(73.5 ± 9.5, 80.4±11.8, p= 0.047, ANOVA F-test, p=0.073, Wilcoxon text), which became
non-significant in the sensitivity analysis.
Demographic information and week 8 and baseline clinical characteristics of the 54 participants
are given in Table 1 and Table 2. The three treatment groups differed at with respect to gender:
12 (92%) of patients receiving olanzapine were male, compared to 16 (76%) and 9 (45%) of
the patients receiving risperidone and molindone, respectively (p=0.009). Patients treated with
olanzapine had higher week 8 aspartate aminotransferase (p=0.004), higher baseline sitting
pulse (p=0.033), and higher fasting triglycerides than the other treatment groups, although this
later finding became non-significant in the nonparametric sensitivity analysis for (p=0.041,
ANOVA F-test; p=0.068, Wilcoxon test). Patients treated with risperidone had higher week 8
prolactin (p<0.0001). Patients treated with molindone had lower week 8 systolic blood pressure
(p=0.030). Also, patients treated with monlindone were prescribed significantly more
concomitant benztropine (beyond the prophylactic benztropine prescribed to all patients treated
with molindone) at week 8 (p= 0.016). Otherwise, demographic and clinical characteristics at
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week 8 did not differ between the three medication treatment groups. Treatment groups differed
at baseline with respect to BPRS-C (p=0.032) and use of concomitant benzodiazepines
(p=0.037), although these differences dissipated by the start of maintenance therapy.
Treatment Discontinuation
Only 14 (26%) of the 54 youths completed the 44-week extension trial (Figure 1). The most
common reasons for study discontinuation were adverse events (N=15), inadequate efficacy
(N=14), and non-adherence with study-related procedures (N=8). Average time to
discontinuation during the maintenance study was 29.9±14.2 weeks among patients receiving
molindone, 23.0±16.6 weeks among patients receiving olanzapine, and 25.3±15.2 among
patients receiving risperidone. Patient time to discontinuation is displayed graphically in Figure
2. While there were no statistically significant treatment group differences in length of
maintenance study participation (p=0.467), the rate of patient discontinuation in the group
treated with molindone was consistently slower than that of the group treated with olanzapine.
Antipsychotic Pharmacotherapy
The mean doses of study medication at week 8 and week 52/end of study, respectively, were
66.5±38.7 mg/day and 76.5±47.2 mg/day for patients receiving molindone, 10.2±5.1 mg/day
and 9.6±5.4 mg/day for patients receiving olanzapine, and 3.3 ± 1.5 mg/day and 3.9±1.4 mg/
day for patients receiving risperidone. No statistically significant differences in antipsychotic
dosage were observed during the maintenance phase in any treatment group.
Concomitant Pharmacotherapy
Forty-nine (91%) patients took some concomitant medication during the extension trial (Table
3); 42 (78%) took a concomitant psychotropic medication. Patients taking molindone were
significantly more likely to have taken a psychotropic concomitant medication during the long-
term study (p=0.018), due to the fact that more molindone-treated patients were taking
concomitant benztropine at week 8. However, there was no difference among the treatment
groups with respect to the number of patients who began additional adjunctive benztropine or
any other concomitant medication during this long-term extension trial.
Outcome Measures
Table 4 shows mean change from week 8 and change from baseline in clinical outcome
measures. Like the acute study, there were no statistically significant differences between
treatment groups in any of the maintenance phase clinical outcomes. However, the change in
CAFAS 8 Total Score during maintenance was notably higher (indicative of worse functioning)
in the group treated with risperidone (molindone: mean change= 0.7±33.9; olanzapine: mean
change=3.3±32.8; risperidone: mean change=29.4±50.9) and was significantly different from
zero (p=0.025).
PANSS total score, the a priori primary outcome measure, as well as all other clinical outcome
measures, varied little over the course of maintenance therapy. Last observation carried forward
mean change from week 8 in PANSS total score was no larger than seven points in either
direction at any of the time points in any treatment group. Despite the lack of significant change
in clinical outcomes during maintenance therapy, significant differences in clinical measures
seen during the acute phase continued to be maintained over the course of the entire 52 week
trial (p≤0.05 for all variables and treatment groups).
Safety and Tolerability
Adverse Events—There were no significant differences among the treatment groups in
adverse events at the beginning of the long term extension. Twenty (37%) patients were
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experiencing at least one adverse event at week 8, but no more than 4 (7%) of all patients
experienced any one type of adverse event at that time point.
The most common reason for study discontinuation during maintenance was adverse events.
Forty-five (83%) of all patients experienced at least one adverse event during the long term
extension (Table 5). Weight gain (39% of all patients) and anxiety (26% of all patients) were
the most common adverse events reported, but the rates of these did not significantly differ
across the treatment groups. Weight gain was associated with treatment discontinuation in 11
patients (Figure 1). All 11 patients who discontinued from TEOSS due to weight gain had
increases in their BMI z-scores during both the acute and maintenance phases. Five of these
patients had greater increases in their BMI z-scores during the acute phase, 3 had larger gains
in their BMI z-score while in the maintenance phase, and 3 had equal increases in BMI z-score
during both phases. Pacing or restlessness was significantly more common in patients receiving
molindone (p=0.018). One serious adverse event, acute suicidal ideation in a patient taking
risperidone, was observed.
Neurological Side Effects—Despite the fact that youths taking molindone reported
significantly more adverse events of pacing or restlessness, no between treatment group
differences were seen in change in NRS total, BAS, and AIMS total neurological measures
during the maintenance study or over the entire 52 week study period (Table 4). Of note, no
patient had persistent abnormal involuntary movement suggestive of tardive dyskinesia.
Weight Gain—All treatment groups showed statistically significant within-group weight
gain and BMI increases during maintenance (Table 4). These increases became less or non-
significant for standardized z-score and percentile measures. In contrast to the antecedent 8
week acute trial, there were no significant differences between treatment groups in change in
weight, weight z-score, BMI, BMI percentile, or BMI z-score during the maintenance phase.
However, patients treated with olanzapine did maintain significant increases in weight z-score,
BMI percentile, and BMI z-score over molindone patients during the entire 52 week study
(p=0.030; p=0.010; p=0.039 respectively).
Laboratory Parameters and Vital Signs—In contrast to the acute trial, patients in the
long term extension generally showed no significant differences across treatment groups in
change from week 8 in laboratory parameters or vital signs and significant treatment differences
in total cholesterol, LDL, insulin, ALT, and AST seen in the acute study were not maintained
over the 52 week trial (Table 6). Patients receiving risperidone again saw the largest change
in prolactin levels versus the other treatment groups during maintenance, but in the opposite
direction. In the long term extension, patients receiving risperidone showed an average
decrease from baseline of 11.2±14.1 mcg/L (p=0.004 for test of change different than zero).
Despite this decrease, patients receiving risperidone maintained higher prolactin levels than
other treatment groups throughout the entire 52 week trial, although this finding became non-
significant in the sensitivity analysis (p=0.045, ANOVA F-test, p=0.077, Wilcoxon test). In
contrast to the acute phase of the study, patients receiving molindone showed the highest
numerical increases in total cholesterol, LDL cholesterol, insulin, alanine aminotransferase,
and aspartate aminotransferase. Patients treated with olanzapine showed a significant change
from baseline in fasting glucose, though this became non-significant in the nonparametric
sensitivity analysis (p=0.011, ANOVA F-test; p=0.125, Wilcoxon test). Although patients
treated with olanzapine had significantly greater increases in pulse and diastolic blood pressure
during the antecedent acute trial (p= 0.002, and p=0.031, respectively), in comparison to those
treated with risperidone or molindone, only patients treated with molindone showed a
significant increase from baseline in systolic blood pressure (p=0.013) during maintenance
therapy. Further, acute differences in pulse and diastolic blood pressure were not maintained
over the entire 52 week study.
Findling et al. Page 7














Overall, 12 % of youth enrolled in TEOSS completed 52 weeks on their originally randomized
treatment. There were no differences in time to discontinuation or symptom reduction between
the three study agents. Across acute and maintenance data, discontinuation rates due to either
inadequate response and/or adverse events are high. In comparison to adult schizophrenia trials,
these findings suggest that youth are less likely to maintain the same treatment over one year.
14–17 In addition, symptom response tended to plateau during maintenance therapy, such that
most youth did not make significant improvements beyond what they had achieved at 8 weeks
of acute treatment.
Adverse events during maintenance treatment were common. Of the 15 subjects who
discontinued their study medication due to side effects, 11 stopped because of weight gain.
Each medication arm was associated with a significant increase in weight. None of the
treatment groups significantly differed in regards to weight gain or other metabolic parameters.
Akathisia was reported significantly more often by youth taking molindone. Elevated prolactin
concentrations noted in subjects on risperidone at the end of the acute trial reduced over
maintenance treatment, but remained elevated at end of study participation.
The lack of significant group metabolic differences during maintenance therapy is perhaps
surprising. Acute TEOSS data found that olanzapine and risperidone were associated with
significant weight gain, and olanzapine was associated with lipid and liver function changes.
3 However, those analyses included subjects that discontinued after participation in the acute
study due to metabolic side effects, whereas these maintenance data include only those that
tolerated acute treatment and continued in this trial. Therefore, there is a selection bias towards
patients that did not develop clinically significant adverse events during acute therapy.
Our maintenance therapy data are limited primarily by sample size and hence statistical power.
Although TEOSS is the largest publicly funded treatment study of EOSS conducted to date,
the sample size for maintenance data provides minimal power to assess for treatment arm
differences. Thus, failure to reject a null hypothesis of no difference among treatments should
not be taken as evidence of no difference. Our inclusion and exclusion criteria may have also
limited generalizability. It should also be noted that it is possible that other available
medications that were not studied in TEOSS would have been more effective and/or tolerable.
Despite these limitations, a key strength of this work is its extended period of blinded treatment.
Another strength of this study is that it demonstrates the pivotal role that medication tolerability
has in the treatment of these vulnerable youth. Such an observation has real world significance.
The maintenance data presented in this paper suggest that these three agents generally maintain
symptom reductions achieved in acute responders with EOSS. However, all three drugs have
significant side effects that affect tolerability as shown by the fact that very few patients
completed one year of treatment.
These data support the need for longer term comparative treatment trials for this patient
population. Short-term placebo-controlled studies are limited in clinical utility if early
responses are not maintained with continued therapy. Ultimately, more effective and safer
treatments are needed for EOSS.
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